FLT3
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB07072 | UNC2025 | 1429881-91-3 | UNC2025 is an inhibitor of Mer and Flt3 with IC50 of 0.8 nM and 0.74 nM, respectively. |
| FB10144 | UNC2025 HCl | 2070015-17-5 | UNC2025 HCl is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3. |
| FB04184 | TCS 359 | 301305-73-7 | TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent inhibitor of FLT3 with IC50 of 42 nM. |
| FB09656 | Tandutinib | 387867-13-2 | Tandutinib is an antagonist of FLT3 with IC50 of 0.22 μM and can also inhibit PDGFR and c-Kit thereby inhibiting cellular proliferation and inducing apoptosis. |
| FB16041 | TAK-659 | 1312691-33-0 | TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL)[1][2][3][4]. |
| FB09056 | SU-5614 | 1055412-47-9 | SU-5614 is an inhibitor of FLT3. In Ba/F3 and AML cell lines expressing a constitutively activated FLT3, SU-5614 exhibits significant cell growth inhibition and cell cycle arrest. |
| FB02032 | Quizartinib | 950769-58-1 | Quizartinib is a second-generation FLT3 inhibitor for Flt3 (ITD/WT) with IC50 of 1.1 nM/4.2 nM, being 10-fold selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. |
| FB02058 | KW-2449 | 1000669-72-6 | KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A, and showing little effect on PDGFRβ, IGF-1R, EGFR. |
| FB02610 | Gilteritinib | 1254053-43-4 | Gilteritinib is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/< 1 nM respectively and shows potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. |
| FB11623 | Gilteritinib Hemifumarate | 1254053-84-3 | Gilteritinib hemifumarate is an inhibitor of FLT3 and AXL with IC50 of 0.29 nM and 0.73 nM, respectively. |
| FB09449 | G-749 | 1457983-28-6 | G-749 is a FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 0.4/0.6/3.5/7.5 nM for Wt Flt3/D835Y/MV4-11/Molm-14 respectively. |
| FB01078 | FLT3-IN-2 | 923562-23-6 | FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM. |
| FB11635 | FLT3-IN-1 Succinate | 1702864-11-6 | FLT3-IN-1 Succinate is a potent FLT3 inhibitor extracted from patent WO2015056683A1, compound example A. |
| FB11634 | FLT3-IN-1 | 1472797-69-5 | FLT3-IN-1 is a potent FLT3 inhibitor extracted from patent WO2015056683A1, compound example A |
| FB01159 | SKLB4771 | 1370256-78-2 | FLT3-IN-1 is a potent and selective Flt3 inhibitor with IC50 of 10 nM and against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM. |
| FB17840 | Fedratinib hydrochloride hydrate | 1374744-69-0 | Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. |
| FB11269 | Famitinib | 1044040-56-3 | Famitinib, a structural analogue of sunitinib, is a multi-targeted receptor tyrosine kinase inhibitor which is potential for treatment of renal cell carcinoma, gastrointestinal stromal tumours, pancreatic cancer, and nasopharyngeal carcinoma. |
| FB02066 | ENMD-2076 Tartrate | 1453868-32-0 | ENMD-2076 tartrate has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. |
| FB06965 | ENMD-2076 | 934353-76-1 | ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. |
| FB16259 | DBPR114 | 2443767-35-7 | DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss. |
| FB12276 | CHMFL-FLT3-122 | 1839150-56-9 | CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor with IC50 of 40 nM. |
| FB17557 | CCT241736 | 1402709-93-6 | CCT241736 is a dual FLT3/Aurora kinase A/B inhibitor with IC50 values of 0.035μM, 0.015μM and 0.1μM, respectively. |
| FB01025 | BPR1J-097 | 1327167-19-0 | BPR1J-097 is a small molecule FLT-3 inhibitor (IC50=11±7 nM) with promising in vivo anti-tumour activities, inhibiting FLT-3 D835Y with an IC50 of 3 nM. |
| FB16406 | ATH686 | 853299-52-2 | ATH686 is the second-generation FLT3 inhibitor. |
| FB12273 | 5'-Fluoroindirubinoxime | 861214-33-7 | 5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) with IC50 of 15 nM. |